Jpmorgan says this drug stock. IT’s One Jim Cramer is itching to buy again
Jpmorgan touts bristol myers squibb as a top biopharma pick. Jim Cramer is also quite fond of it. The news in a Friday Note, jpmorgan analysts said bristol myers is well positioned to “further re-rate” as cobenfy goes wider. The Oral Drug Designed to Help Treat Adults with Schizophrenia has the potential to bring peak … Read more